Proteomic analysis reveals upregulation of calreticulin in murine dopaminergic neuronal cells after treatment with 6-hydroxydopamine

Neuroscience Letters

Volumn 352, Issue 1, 2003, Pages 17-20

  Lee, Young Mook ^a   Park, Seong H ^a   Chung, Kwang C ^a   Oh, Young J ^a  

^a Yonsei University   (South Korea)

Author keywords

2 Dimensional gel; 6 Hydroxydopamine; Calreticulin; Matrix assisted laser desorption ionizing time of flight; MN9D cells

Indexed keywords

ANTIOXIDANT; CALRETICULIN; CASPASE INHIBITOR; CHAPERONE; NEUROTOXIN; OXIDOPAMINE; PROTEIN ANTIBODY;

ANIMAL CELL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DATA ANALYSIS; DOPAMINERGIC NERVE CELL; DOWN REGULATION; GEL ELECTROPHORESIS; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PARKINSON DISEASE; PHENOMENOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEOMICS; RAT; TECHNOLOGY; UPREGULATION;

EID: 0242542672     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2003.08.018     Document Type: Article

References (18)

1. Arnaudeau S., Frieden M., Nakamura K., Castelbou C., Michalak M., Demaurex N. Calreticulin differentially modulates calcium uptake and release in the endoplasmic reticulum and mitochondria. J. Biol. Chem. 277:2002;46696-46705.
2. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2:2001;325-332.
3. +-induced dopaminergic neuronal cell death: role of caspases, ROS and JNK. J. Neurosci. Res. 57:1999;86-94.
4. Ferri K.F., Kroemer G. Organelle-specific initiation of cell death pathways. Nat. Cell Biol. 3:2001;E255-E263.
5. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55:1996;259-272.
6. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2:2001;492-501.
7. Han B.S., Hong H.S., Choi W.S., Markelonis G.J., Oh T.H., Oh Y.J. Caspase-dependent and -independent cell death pathways in primary cultures of mesencephalic dopaminergic neurons after neurotoxin treatment. J. Neurosci. 23:2003;5069-5078.
8. + or by 6-hydroxydopamine in cultured rat cortical neurons: degradation and dephosphorylation of tau. Neurosci. Lett. 341:2003;99-102.
9. Hartmann A., Hirsch E.C. Parkinson's disease: the apoptosis hypothesis revisited. Adv. Neurol. 86:2001;143-153.
10. Imai Y., Soda M., Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275:2000;35661-35664.
11. Johnson R.J., Xiao G., Shanmugaratnam J., Fine R.E. Calreticulin functions as a molecular chaperone for the beta-amyloid precursor protein. Neurobiol. Aging. 22:2001;387-395.
12. 2+ increase and cell death. J. Biol. Chem. 273:1998;12858-12862.
13. McNaught K.S., Olanow C.W., Halliwell B., Isacson O., Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2:2001;589-594.
14. Nakamura K., Bossy-Wetzel E., Burns K., Fadel M.P., Lozyk M., Goping I.S., Opas M., Bleackley C., Green D.R., Michalak M. Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis. J. Cell Biol. 150:2000;731-740.
15. Nunez M.T., Osorio A., Tapia V., Vergara A., Mura C.V. Iron-induced oxidative stress up-regulates calreticulin levels in intestinal epithelial (Caco-2) cells. J. Cell. Biochem. 82:2001;660-665.
16. Shimura H., Hattori N., Kubo S.-I., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25:2000;302-305.
17. Spiro R.G., Zhu Q., Bhoyroo V., Soling H.D. Definition of the lectin-like properties of the molecular chaperone, calreticulin, and demonstration of its copurification with endomannosidase from rat liver Golgi. J. Biol. Chem. 271:1996;11588-11594.
18. Taguchi J., Fujii A., Fujino Y., Tsujioka Y., Takahashi M., Tsuboi Y., Wada I., Yamada T. Different expression of calreticulin and immunoglobulin binding protein in Alzheimer's disease brain. Acta Neuropathol. 100:2000;153-160.